Patents by Inventor William L. Matier
William L. Matier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 4501912Abstract: A method for the treatment of glaucoma or lowering intraocular pressure in a mammal, involving topically administering to the eye of such mammal a selectively metabolized beta-blocking compound of the formula ##STR1## wherein R may be lower alkyl, lower hydroxyalkyl, lower alkynyl, aralkyl, or an ester-containing group and Ar may be substituted or unsubstituted aromatic; or a pharmaceutically acceptable salt thereof. Because of a relatively long duration of action of such compounds in ocular fluids and a relatively short duration of action in the systemic circulation, such compounds are useful for the treatment of excessive intraocular pressure without substantial systemic effects.Type: GrantFiled: December 13, 1982Date of Patent: February 26, 1985Assignee: American Hospital Supply CorporationInventors: William L. Matier, Sheung-Tsam Kam
-
Patent number: 4466965Abstract: The present invention relates to new compounds of the formula ##STR1## alkylene, or --S-- where R.sub.1 is hydrogen, alkyl, or aryl; W is hydrogen, hydroxy, amino, alkyloxy, aryloxy, O-alkyl, or O-aralkyl; (Y).sub.A is --CH.sub.2 NR.sub.2 R.sub.3 where R.sub.2 and R.sub.3 may be hydrogen, substituted alkyls, aryls, or together with N form a 5 to 7 membered heterocyclic group; and Ar is a substituted or unsubstituted heteroaryl. These compounds are useful in the treatment of various cardiac arrhythmias.Type: GrantFiled: July 26, 1982Date of Patent: August 21, 1984Assignee: American Hospital Supply CorporationInventors: David M. Stout, William L. Matier
-
Patent number: 4455317Abstract: A method for the treatment of glaucoma or lowering intraocular pressure in a mammal, involving topically administering to the eye of such mammal a selectively metabolized beta-blocking compound of the formula: ##STR1## wherein Ar may be substituted or unsubstituted aromatic, Y may be a straight or branched carbon chain or aralkyl, R may be lower alkyl, lower alkenyl, lower alkynyl, aryl, or aralkyl, and x is an integer from 1 to about 3; or a pharmaceutically acceptable salt thereof. Because of a relatively long duration of action of such compounds in ocular fluids and a relatively short duration of action in the systemic circulation, such compounds are useful for the treatment of excessive intraocular pressure without substantial systemic effects.Type: GrantFiled: June 23, 1981Date of Patent: June 19, 1984Assignee: American Hospital Supply CorporationInventor: William L. Matier
-
Patent number: 4454154Abstract: A method for the treatment of glaucoma or lowering intraocular pressure in a mammal, involving topically administering to the eye of such mammal a selectively metabolized beta-blocking compound of the formula ##STR1## wherein R may be lower alkyl, lower alkynyl aryl, or aralkyl; A may be a direct bond, lower alkylenyl, or lower alkenyl; x may be an integer from 1 to 3; Ar may be substituted or unsubstituted aromatic; R.sub.1 may be lower alkyl, lower hydroxy alkyl, lower alkenyl, lower alkynyl, or aralkyl; and pharmaceutically accepted salts thereof. Because of a relatively long duration of action of such compounds in ocular fluids and a relatively short duration of action in the systemic circulation, such compounds are useful for the treatment of excessive intraocular pressure without substantial systemic side effects.Type: GrantFiled: June 23, 1981Date of Patent: June 12, 1984Assignee: American Hospital Supply CorporationInventor: William L. Matier
-
Patent number: 4402974Abstract: A method for the treatment of glaucoma or lowering intraocular pressure in a mammal, involving topically administering to the eye of such mammal a selectively metabolized beta-blocking compound of the formula ##STR1## wherein R may be lower alkyl, lower hydroxyalkyl, lower alkynyl, aralkyl, or an ester-containing group and Ar may be substituted or unsubstituted aromatic; or a pharmaceutically acceptable salt thereof. Because of a relatively long duration of action of such compounds in ocular fluids and a relatively short duration of action in the systemic circulation, such compounds are useful for the treatment of excessive intraocular pressure without substantial systemic effects.Type: GrantFiled: June 23, 1981Date of Patent: September 6, 1983Assignee: American Hospital Supply CorporationInventors: William L. Matier, Sheung-Tsam Kam
-
Patent number: 4334088Abstract: Indanyloxy compounds having 2-alkynyl substituents which exhibit diuretic, saluretic, and uricosuric activity are described. The compounds are obtained according to a process involving selective etherification of a 5-hydroxyindanone followed by alkynylation with a silylated alkynyl bromide to provide novel silylated intermediates which are hydrolyzed to indanyloxy compounds such as (6,7-dichloro-1-oxo-2-phenyl-2-propargyl-5-indanyloxy)acetic acid.Type: GrantFiled: May 21, 1981Date of Patent: June 8, 1982Assignee: Mead Johnson & CompanyInventors: Porter C. Johnson, William L. Matier
-
Patent number: 4321398Abstract: Substituted 1-phenoxy-3-(thienyl-tert.-butylamino)-2-propanols and related 3-benzothienyl compounds are selective .beta.-receptor blocking agents. Preferred compounds bear an ortho-substituent on the phenoxy ring.Type: GrantFiled: May 7, 1981Date of Patent: March 23, 1982Assignee: Mead Johnson & CompanyInventors: William L. Matier, William E. Kreighbaum
-
Patent number: 4291168Abstract: Indanyloxy compounds having 2-alkynyl substituents which exhibit diuretic, saluretic, and uricosuric activity are described. The compounds are obtained according to a process involving selective etherification of a 5-hydroxyindanone followed by alkynylation with a silylated alkynyl bromide to provide novel silylated intermediates which are hydrolyzed to indanyloxy compounds such as (6,7-dichloro-1-oxo-2-phenyl-2-propargyl-5-indanyloxy)acetic acid.Type: GrantFiled: September 24, 1980Date of Patent: September 22, 1981Assignee: Mead Johnson & CompanyInventors: Porter C. Johnson, William L. Matier
-
Patent number: 4259482Abstract: Styrylamidines are prepared by treating styrylsulfonylamidines with base. The styrylamidines are effective in the prevention of aggregation of blood platelets and as analgesics. Compounds of the invention are also useful as anticonvulsants, diuretics, and antihypertensive agents. The styrylsulfonylamidines of the invention which serve as precursors to the styrylamidines also have analgesic properties. Illustrative of the styrylamidines of the present invention are 4-amino-N-(4-aminostyryl)benzamidine and N-(3,4-dichlorostyryl)acetamidine. An example of a styrylsulfonylamidine is N-(styrylsulfonyl)acetamidine.Type: GrantFiled: December 17, 1979Date of Patent: March 31, 1981Assignee: Mead Johnson & CompanyInventors: William L. Matier, William T. Comer
-
Patent number: 4247715Abstract: Indanyloxy compounds having 2-alkynyl substituents which exhibit diuretic, saluretic, and uricosuric activity are described. The compounds are obtained according to a process involving selective etherification of a 5-hydroxyindanone followed by alkynylation with a silylated alkynyl bromide to provide novel silylated intermediates which are hydrolyzed to indanyloxy compounds such as (6,7-dichloro-1-oxo-2-phenyl-2-propargyl-5-indanyloxy)acetic acid.Type: GrantFiled: April 9, 1979Date of Patent: January 27, 1981Assignee: Mead Johnson & CompanyInventors: Porter C. Johnson, William L. Matier
-
Patent number: 4243681Abstract: A new class of alkylthiophenoxypropanolamine derivatives and methods for preparation are described. The compounds have vasodilating and antispasmodic activity, inhibit blood platelet aggregation and are substantially free of beta-adrenergic blocking effects. They are particularly valuable in the treatment of disease states responsive to vasodilation such as obstructive peripheral vascular diseases and cerebral vascular deficiencies. A representative and preferred embodiment of the invention consists of 1-[4-(1-methylethylthio)phenoxy]-3-(octylamino)-2-propanol.Type: GrantFiled: April 16, 1979Date of Patent: January 6, 1981Assignee: Mead Johnson & CompanyInventors: Duane F. Morrow, William L. Matier
-
Patent number: 4206142Abstract: Styrylamidines are prepared by treating styrylsulfonylamidines with base. The styrylamidines are effective in the prevention of aggregation of blood platelets and as analgesics. Compounds of the invention are also useful as anticonvulsants, diuretics, and antihypertensive agents. The styrylsulfonylamidines of the invention which serve as precursors to the styrylamidines also have analgesic properties. Illustrative of the styrylamidines of the present invention are 4-amino-N-(4-aminostyryl)benzamidine and N-(3,4-dichlorostyryl)acetamidine. An example of a styrylsulfonylamidine is N-(styrylsulfonyl)acetamidine.Type: GrantFiled: October 6, 1978Date of Patent: June 3, 1980Assignee: Mead Johnson & CompanyInventors: William L. Matier, William T. Comer
-
Patent number: 4148908Abstract: Preparation of cyanomethylphenethanolamines useful as adrenergic stimulants is described. Preferred compounds such as 2-hydroxy-5-[1-hydroxy-2-[(1,1-dimethyl-2-phenylethyl)amino]ethyl]-benzene acetonitrile are selective beta-adrenergic stimulants having relatively greater potency on respiratory smooth muscle than on cardiac muscle. Such compounds are particularly valuable in the treatment of bronchial conditions.Type: GrantFiled: September 22, 1977Date of Patent: April 10, 1979Assignee: Mead Johnson & CompanyInventors: William E. Kreighbaum, William L. Matier, Herbert R. Roth
-
Patent number: 4130663Abstract: Styrylamidines are prepared by treating styrylsulfonylamidines with base. The styrylamidines are effective in the prevention of aggregation of blood platelets and as analgesics. Compounds of the invention are also useful as anticonvulsants, diuretics, and antihypertensive agents. The styrylsulfonylamidines of the invention which serve as precursors to the styrylamidines also have analgesic properties. Illustrative of the styrylamidines of the present invention are 4-amino-N-(4-aminostyryl)benzamidine and N-(3,4-dichlorostyryl)acetamidine. An example of a styrylsulfonylamidine is N-(styrylsulfonyl)acetamidine.Type: GrantFiled: April 10, 1978Date of Patent: December 19, 1978Assignee: Mead Johnson & CompanyInventors: William L. Matier, William T. Comer
-
Patent number: 4096183Abstract: Styrylamidines are prepared by treating styrylsulfonylamidines with base. The styrylamidines are effective in the prevention of aggregation of blood platelets and as analgesics. Compounds of the invention are also useful as anticonvulsants, diuretics and antihypertensive agents. The styrylsulfonylamidines of the invention which serve as precursors to the styrylamidines also have analgesic properties. Illustrative of the styrylamidines of the present invention are 4-amino-N-(4-aminostyryl)benzamidine and N-(3,4-dichlorostyryl)acetamidine. An example of a styrylsulfonylamidine is N-(styrylsulfonyl)acetamidine.Type: GrantFiled: August 19, 1977Date of Patent: June 20, 1978Assignee: Mead Johnson & CompanyInventors: William L. Matier, William T. Comer
-
Patent number: 4055658Abstract: Preparation of cyanomethylphenethanolamines useful as adrenergic stimulants is described. Preferred compounds such as 2-hydroxy-5-[1-hydroxy-2-[(1,1-dimethyl-2-phenylethyl)amino]ethyl]-benzene acetonitrile are selective beta-adrenergic stimulants having relatively greater potency on respiratory smooth muscle than on cardiac muscle. Such compounds are particularly valuable in the treatment of bronchial conditions.Type: GrantFiled: May 17, 1976Date of Patent: October 25, 1977Assignee: Mead Johnson & CompanyInventors: William E. Kreighbaum, William L. Matier, Herbert R. Roth
-
Patent number: 4052455Abstract: Styrylamidines are prepared by treating styrylsulfonylamidines with base. The styrylamidines are effective in the prevention of aggregation of blood platelets and as analgesics. Compounds of the invention are also useful as anticonvulsants, diuretics and antihypertensive agents. The styrylsulfonylamidines of the invention which serve as precursors to the styrylamidines also have analgesic properties. Illustrative of the styrylamidines of the present invention are 4-amino-N-(4-aminostyryl)benzamidine and N-(3,4-dichlorostyryl)acetamidine. An example of a styrylsulfonylamidine is N-(styrylsulfonyl)acetamidine.Type: GrantFiled: August 4, 1975Date of Patent: October 4, 1977Assignee: Mead Johnson & CompanyInventors: William L. Matier, William T. Comer